New Breath-Test Device Aims to Support Asthma Diagnosis and Monitoring

A new generation of breath-testing technology has been introduced to support healthcare professionals in assessing airway inflammation and managing respiratory conditions. The device, called NIOX PRO is designed to make fractional exhaled nitric oxide (FeNO) testing easier to incorporate into routine respiratory care.

FeNO testing measures the amount of nitric oxide in a person’s exhaled breath.

This can help clinicians assess certain types of airway inflammation, which is relevant to asthma diagnosis and treatment decisions.

How Does FeNO Testing Work?

When inflammation affects the airways, particularly inflammation associated with type 2 immune responses, nitric oxide levels in exhaled breath may rise. A FeNO test measures this gas through a simple breathing procedure.

The result provides an additional piece of information for clinicians assessing people with suspected or existing asthma.

It can help inform decisions about treatment, including whether inflammation may respond to certain anti-inflammatory medicines.

However, FeNO testing is not a standalone test for every respiratory condition. Results need to be interpreted alongside symptoms, medical history and other lung-function assessments.

What Is New About NIOX PRO?

According to the product announcement, NIOX PRO builds on an earlier testing platform while adding updated usability, portability and connectivity features.

The device is designed to help healthcare professionals carry out tests and manage results more conveniently. Its planned integration with a cloud-based application is intended to support digital data management and clinical workflows.

These features may be useful in healthcare settings where clinicians need to assess airway inflammation and monitor patients over time. However, the practical benefits will depend on how the device performs and is adopted in real-world care.

What Could This Mean for Asthma Care?

Asthma symptoms and airway inflammation can vary over time. Additional objective measurements may help clinicians understand a patient’s condition and make more informed decisions about management.

FeNO testing can complement symptom assessments and other lung-function tests, but it does not replace a full clinical evaluation. A single result cannot independently confirm every asthma diagnosis or determine the right treatment for every patient.

The device announcement does not itself establish that NIOX PRO improves asthma outcomes compared with existing testing options. Further independent evidence would be needed to assess its impact on diagnosis, treatment and long-term disease control.

The post New Breath-Test Device Aims to Support Asthma Diagnosis and Monitoring first appeared on newsremind.com.